Virosome: A novel vector to enable multi-modal strategies for cancer therapy

Advanced Drug Delivery Reviews

Volumn 64, Issue 8, 2012, Pages 730-738

  Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti tumor immunity; Apoptosis; Fusion protein; Pseudovirion; RNA; Synthetic vector; Virus

Indexed keywords

ANTI-TUMOR ACTIVITIES; ANTICANCER DRUG; ANTITUMOR DRUGS; ANTITUMOR IMMUNITY; CANCER THERAPY; DRUG DELIVERY SYSTEM; FUSION PROTEINS; HEPATITIS B VIRUS; INFLUENZA VIRUS; MULTI-MODAL; NONVIRAL VECTORS; PSEUDOVIRION; SENDAI VIRUS; SINGLE-MODAL; SYNTHETIC VECTOR; VIRAL GENOME;

CELL DEATH; DISEASE CONTROL; DISEASES; DRUG DELIVERY; GENES; ONCOLOGY; RNA; VIRUSES;

VECTORS;

ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA INTERFERON; BLEOMYCIN; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GANCICLOVIR; HYBRID PROTEIN; INTERLEUKIN 6; LIPOFECTIN; LIPOSOME; PLASMID DNA; RETINOIC ACID INDUCIBLE PROTEIN I; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; VIROSOME;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER REGRESSION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTROPORATION; GENE; HEPATITIS B VIRUS; HERPES SIMPLEX VIRUS THYMIDINE KINASE GENE; HUMAN; INFLAMMATION; INFLUENZA VIRUS; INTESTINAL BLEEDING; LIVER CELL CARCINOMA; MELANOMA; MELANOMA ASSOCIATED ANTIGEN GENE; NATURAL KILLER CELL; NONHUMAN; PARAINFLUENZA VIRUS 1; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS ENTRY; VIRUS GENOME; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; GENETIC VECTORS; HUMANS; NEOPLASMS; VIROSOMES;

EID: 84860620259     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.03.007     Document Type: Review

References (112)

1. Mulligan R.C. The basic science of gene therapy. Science 1993, 260:926.
2. Ledley F.D. Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum. Gene Ther. 1995, 6:1129-1144.
3. Li S., Huang L. Nonviral gene therapy: promises and challenges. Gene Ther. 2000, 7:31-34.
4. Lam P.Y., Breakefield X.O. Hybrid vector designs to control the delivery, fate and expression of transgenes. J. Gene Med. 2000, 2:395-408.
5. Verma I.M., Weitzman M.D. Gene therapy: twenty-first century medicine. Annu. Rev. Biochem. 2005, 7(4):711-738.
6. Baum C., Schambach A., Bohne J., et al. Retrovirus vectors; toward the plentivirus?. Mol. Ther. 2006, 13:1050-1063.
7. Li C., Boweles D., van Dyke T., et al. Adeno-associated virus vectors; potential applications for cancer gene therapy. Cancer Gene Ther. 2005, 12:913-925.
8. Young L.S., Searle P.F., Onion D., et al. Viral gene therapy strategies: from basic science to clinical application. J. Pathol. 2006, 208:299-318.
9. Kaneda Y., Tabata Y. Non-viral vectors for cancer therapy. Cancer Sci. 2006, 97:348-354.
10. Morille M., Passirani C., Vonalbourg A., et al. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008, 29:3477-3496.
11. Al-Dosari M.S., Gao X. Nonviral gene delivery: principle, limitations, and recent progress. AAPS J. 2009, 11:671-681.
12. Wattiaux R., Laurent N., Wattiaux-De Coninck S., et al. Endosomes, lysosomes: their implication in gene transfer. Adv. Drug Deliv. Rev. 2000, 41:201-208.
13. Zabner J., Fasbender A.J., Moninger T., et al. Cellular and molecular barriers to gene transfer by a cationic lipid. J. Biol. Chem. 2005, 280:12255-12261.
14. Kaneda Y. Biological barriers to gene therapy. Polymeric Gene Delivery 2005, 29-42. CRC Press, Florida. M. Amiji (Ed.).
15. Farhood H., Serbina N., Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta 1995, 1235:289-295.
16. El Ouahabi A., Thiry M., Pector V., et al. The role of endosome destabilizing activity in the gene transfer process mediated by cationic lipids. FEBS Lett. 1997, 414:187-192.
17. Neu M., Fischer D., Kissel T. Recent advances in rational gene transfer vector design based on poly (ethylene imine) and its derivatives. J. Gene Med. 2005, 7:992-1009.
18. Seth P. Mechanism of adenovirus-mediated endosome lysis: role of the intact adenovirus capsid structure. Biochem. Biophys. Res. Commun. 1994, 205:1318-1324.
19. Greber U.F., Webster P., Weber J., et al. The role of the adenovirus protease on virus entry into cells. EMBO J. 1996, 15:1766-1777.
20. Zanta M.A., Belguise-Valladier P., Behr J.P. Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc. Natl Acad. Sci. U.S.A. 1999, 96:91-96.
21. Subramanian A., Ranganathan P., Diamond S.L. Nuclear targeting peptide scaffolds for lipofection of nondividing mammalian cells. Nat. Biotechnol. 1999, 17:873-877.
22. Ma H., Zhu J., Maronski M., et al. Non-classical nuclear localization signal peptides for high efficiency lipofection of primary neurons and neuronal cell lines. Neuroscience 2002, 112:1-5.
23. Dean D.A. Import of plasmid DNA into the nucleus is sequence specific. Exp. Cell Res. 1997, 230:293-302.
24. Wilson G.L., Dean B.S., Wang G., et al. Nuclear import of plasmid DNA in digitonin-permeabilized cells requires both cytoplasmic factors and specific DNA sequences. J. Biol. Chem. 1999, 274:22025-22032.
25. Izaurralde E., Kann M., Pante N., et al. EMBO workshop report viruses, microorganisms and scientists meet the nuclear pore Leysin, VD, Switzerland, February 26-March 1, 1998. EMBO J. 1999, 18:289-296.
26. Yazawa K., Fujimori M., Amano J., et al. Bifidobacterium longum as a delivery system for cancer gene therapy; selective localization and growth in hypoxic tumors. Cancer Gene Ther. 2000, 7:269-274.
27. Liu S.-C., Minton N.P., Giaccia A.J., et al. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 2002, 9:291-296.
28. Nakamura T., Sakaki T., Fujimori M., et al. Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors. Biosci. Biotechnol. Biochem. 2002, 66:2362-2366.
29. Kaneda Y., Saeki Y., Morishita R. Gene therapy using HVJ-liposomes; the best of both worlds. Mol. Med. Today 1999, 5:298-303.
30. Okada Y. Sendai virus-induced cell fusion. Methods in Enzymology 1993, vol. 221:18-41. Academic Press, Inc., San Diego. N. Duzgunes (Ed.).
31. Nakamura N., Hart D.A., Frank C.B., et al. Efficient transfer of intact oligonucleotides into the nucleus of ligament scar fibroblasts by HVJ-cationic liposomes is correlated with effective antisense gene inhibition. J. Biochem. 2001, 129:755-759.
32. Zhou W.-Z., Hoon D.S.B., Huang S.K.S., et al. RNA melanoma vaccine; induction of anti-tumor immunity by human gp100 mRNA immunization. Hum. Gene Ther. 1999, 10:2719-2724.
33. Kawashita Y., Ohtsuru A., Miki F., et al. Eradication of hepatocellular carcinoma xenografts by radiolabelled lipiodol-inducible gene therapy. Gene Ther. 2005, 12:1633-1639.
34. Bagai S., Sarkar D.P. Targeted delivery of hygromycin B using reconstituted Sendai viral envelopes lacking hemagglutinin-neuraminidase. FEBS Lett. 1993, 326:183-188.
35. Ramani K., Bora R.S., Kumar M., et al. Novel gene delivery to liver cells using engineered virosomes. FEBS Lett. 1997, 404:164-168.
36. Ramani K., Hassan O., Venkaiah B., et al. Site-specific gene delivery in vivo through engineered Sendai virus envelope. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:11886-11890.
37. Uchida T., Kim J., Yamaizumi M., et al. Reconstitution of lipid vesicles associated with HVJ (Sendai virus) sikes. Purification and some properties of vesicles containing nontoxic fragment A of diphtheria toxin. J. Cell Biol. 1979, 80:10-20.
38. Suzuki K., Nakashima H., Sawa Y., et al. Reconstituted fusion liposomes for gene transfer in vitro and in vivo. Gene Ther. Reg. 2000, 1:65-77.
39. Steinhauer D.A., Skehel J.J. Genetics of influenza virus. Annu. Rev. Genet. 2002, 36:305-332.
40. Wiley D.C., Skehel J.J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 1987, 56:365-394.
41. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry; the influenza hemagglutinin. Annu. Rev. Biochem. 2000, 69:531-569.
42. Ohuchi M., Asaoka N., Sakai T., et al. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect. 2006, 8:1287-1293.
43. Wagner R., Matrosovich M., Klenk H.D. Functional balance between haemagglutinin and neuraminidase in influenza virus infection. Rev. Med. Virol. 2002, 12:159-166.
44. Wagner E., Plank C., Zatloukal K., et al. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:7934-7938.
45. de Jonge J., Holtrop M., Wilschut J., et al. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther. 2006, 13:400-411.
46. Zalipsky S., Hansen C.B., Oaks J.M., et al. Evaluation of blood clearance rates and biodistribution of poly(2oxazoline)-grafted liposomes. J. Pharm. Sci. 1996, 85:133-137.
47. Weissig V., Whiteman K.R., Torchilin V.P. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm. Res. 1998, 15:1552-1556.
48. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles; critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42:463-478.
49. Chams V., Bonnafous P., Stegmann T. Influenza hemagglutinin mediated fusion of membrane containing poly(ethylene-glycol) grafted lipids; new insights into the fusion mechanism. FEBS Lett. 1999, 448:28-32.
50. Mastrobattista E., Scoen P., Wilscchut J., et al. Targeting influenza virosomes to ovarian carcinoma cells. FEBS Lett. 2001, 509:71-76.
51. Waelti E., Wegmann N., Schwaninger R., et al. Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Cancer Res. 2002, 62:437-444.
52. Takimoto T., Murti K.G., Bousse T., et al. Role of matrix and fusion proteins in budding of Sendai virus. J. Virol. 2001, 75:11384-11391.
53. Yamada T., Iwasaki Y., Tada H., et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat. Biotechnol. 2003, 21:885-890.
54. Iwasaki Y., Ueda M., Yamada T., et al. Gene therapy of liver tumors with human liver-specific nanoparticles. Cancer Gene Ther. 2007, 14:74-81.
55. Oess S., Hildt E. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Ther. 2000, 7:750-758.
56. Kasuya T., Kuroda S. Nanoparticles for human liver-specific drug and gene delivery systems; in vitro and in vivo advances. Expert Opin. Drug Deliv. 2009, 6:39-52.
57. Kaneda Y., Nakajima T., Nishikawa T., et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol. Ther. 2002, 6:219-226.
58. Kaneda Y., Yamamoto S., Nakajima T. Development of HVJ envelope vector and its application to gene therapy. Non-Viral Vectors for Gene Therapy 2005, 307-332. Elsevier Academic Press. L. Huang, M.-C. Hung, E. Wagner (Eds.).
59. Suvanasuthi S., Tamai K., Kaneda Y. Rapid transport of plasmid DNA into the nucleolus via actin depolymerization using the HVJ envelope vector. J. Gene Med. 2007, 9:55-62.
60. Hirano T., Fujimoto J., Ueki T., et al. Persistent gene expression in rat liver in-vivo by repetitive transfections using HVJ liposome. Gene Ther. 1998, 5:459-464.
61. Mima H., Tomoshige R., Kanamori T., et al. Biocompatible polymer enhances the in vitro and in vivo transfection efficiency of HVJ envelope vector. J. Gene Med. 2005, 7:888-897.
62. Kotani H., Nakajima T., Lai S., et al. The HVJ-envelope as an innovative vector system for cardiovascular disease. Curr. Gene Ther. 2004, 4:183-194.
63. Kawachi M., Tamai K., Saga K., et al. Development of tissue-targeting HVJ envelope vector for successful delivery of therapeutic gene to mouse skin. Hum. Gene Ther. 2007, 18:881-894.
64. Shimbo T., Kawachi M., Saga K., et al. Development of a transferrin receptor-targeting HVJ-E vector. Biochem. Biophys. Res. Commun. 2007, 364:423-428.
65. Daniels T.R., Delgado T., Rodriguez J.A., et al. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 2006, 121:144-158.
66. Pun S.H., Tack F., Bellocq N.C., et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol. Ther. 2004, 3:641-650.
67. Kircheis R., Wagner E. Transferrin receptor-targeted gene delivery systems. Polymeric Gene Delivery 2005, 537-556. CRC Press LLC, Florida. M.M. Amiji (Ed.).
68. Daniels T.R., Delgado T., Helguera G., et al. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 2006, 121:159-176.
69. Saga K., Tamai K., Kawachi M., et al. Functional modification of Sendai virus by siRNA. J. Biotechnol. 2008, 133:386-394.
70. Sudimack J., Lee R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 2000, 41:147-162.
71. Morris J.C., Waldmann T.A. Antibody-based therapy of leukaemia. Expert Rev. Mol. Med. 2009, 11:e29.
72. Vallera D.A., Chen H., Sicheneder A.R., et al. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk. Res. 2009, 33:1233-1242.
73. A. van Waarde, A.A.Rybczynska, N.Ramakrishnan, et al. Sigma Receptors in Oncology: Therapeutic and Diagnostic Applications of Sigma Ligands. Curr. Pharm. Des. 2010, 16:3519-3537.
74. Kirkwood J.M., Tarhini A.A., Panelli M.C., et al. Next generation of immunotherapy for melanoma. J. Clin. Oncol. 2008, 20:3445-3455.
75. Samuel M., Chow P.K., Chan S.-Y., et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Database Syst. Rev. Jan 2009, 21(1):CD001199.
76. Semple S.C., Harasym T.O., Clow K.A., et al. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J. Pharmacol. Exp. Ther. 2005, 312:1020-1026.
77. Zhao H., Hemmi H., Akira S., et al. Contribution of toll-like receptor 9 signaling to the acute inflammatory response to nonviral vectors. Mol. Ther. 2004, 9:241-248.
78. Yew N.S., Scheule R.K. Toxicity of cationic lipid-DNA complexes. Adv. Genet. 2005, 53:189-214.
79. Almeida J.D., Edwards D.C., Brabd C.M., et al. Formation of virosomes from influenza subunits and liposomes. Lancet 1975, 2:899-901.
80. Huckriede A., Bungener L., Daemen T., et al. Influenza virosomes in vaccine development. Methods Enzymol. 2003, 373:74-91.
81. Adamina M., Schumacher R., Zajac P., et al. Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy. J. Liposome Res. 2006, 16:195-204.
82. Felnerova D., Viret J.F., Glück R., et al. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 2004, 15:518-529.
83. Kelly E., Russell S.J. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 2007, 15:651-659.
84. Liu T.C., Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 2008, 15:877-884.
85. Kirn D.H., Thorne S.H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 2009, 9:64-71.
86. Kawaguchi Y., Miyamoto Y., Inoue T., et al. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int. J. Cancer 2009, 124:2478-2487.
87. Tanaka M., Shimbo T., Kikuchi Y., et al. Sterile alpha motif containing domain 9 (SAMD9) is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon. Int. J. Cancer 2010, 126:1982-1991.
88. Kurooka M., Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res. 2007, 67:227-236.
89. Fujihara A., Kurooka M., Miki T., et al. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol. Immunother. 2008, 57:73-84.
90. Takeuchi O., Akira S. Innate immunity to virus infection. Immunol. Rev. 2009, 227:75-86.
91. Yoneyama M., Fujita T. Recognition of viral nucleic acids in innate immunity. Rev. Med. Virol. 2010, 20:4-22.
92. Kato H., Takeuchi O., Sato S., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441:101-105.
93. Schlee M., Hartmann E., Coch C., et al. Approaching the RNA ligand for RIG-I?. Immunol. Rev. 2009, 227:66-74.
94. Ting J.P.Y., Duncan J.A., Lei Y. How the noninflammasome NLRs function in the innate immune system. Science 2010, 327:286-290.
95. Seth R.B., Sun L., Ea C.K., et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005, 122:669-682.
96. Tang E.D., Wang C.Y. TRAF5 is a downstream target of MAVS in antiviral innate immune signaling. PLoS ONE 2010, 5(2):e9172.
97. O'Neill D., Bhardwaj N. Exploiting dendritic cells for active immunotherapy of cancer and chronic infection. Methods Mol. Med. 2005, 109:1-18.
98. Gross S., Walde P. Immunosuppressive mechanisms in human tumors; why we still cannot cure cancer. Immunol Lett. 2008, 116:7-14.
99. Rosenberg S. Progress in human tumour immunology and immunotherapy. Nature 2001, 411:380-384.
100. Dudley M.E., Yang J.C., Sherry R., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.
101. Vignali D.A.A., Collison L.W., Workman C.J. How regulatory T cell work. Nat. Rev. Immunol. 2008, 8:523-532.
102. Cosmin-Anduix B., Lee Y., Jalil J., et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J. Transl. Med. 2008, 6:1-14.
103. + T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
104. Lal G., Zhang N., van der Touw W., et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol. 2009, 182:259-273.
105. Suzuki H., Kurooka M., Hiroaki Y., et al. Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner. FEBS Lett. 2008, 582:1325-1329.
106. Germano G., Allavena P., Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine 2008, 43:374-379.
107. Zorko M., Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Deliv. Rev. 2005, 57:529-545.
108. Sadler J., Williams B.R.G. Interferon-inducible antiviral effects. Nat. Rev. Immunol. 2008, 8:559-568.
109. Besch R., Poeck H., Nohenauer T., et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J. Clin. Invest. 2009, 119:2399-2411.
110. Kawano H., Komaba S., Kanamori T., et al. A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy. BMC Med. 2007, 5:28.
111. Matsuda M., Yamamoto T., Matsumura A., Kaneda Y. Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope. Gene Ther. 2009, 16:1465-1476.
112. M.Matsuda, K Nimura, T Shimbo, et al. Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma. J. Neurooncol. 2011, 103:19-31.